NCT01427699View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2012

Conditions
Type 2 Diabetes
Interventions
DRUG

T2-18C3 therapeutic antibody

1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.

Trial Locations (1)

CH-4031

University Hospital of Basel, Basel

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01427699 - A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter